BBI Solutions expands infectious disease reagent suite
BBI Solutions has demonstrated internal antibody development capabilities and has also expanded its infectious disease reagent suite
Breaking News
Cambrex expands generic API research capabilities
The specialist manufacturer of small molecule innovator and generic active pharmaceutical ingredients will expand its ...
Tonnes of regulatory grief solved by the experts at SWC
Süd-West-Chemie GmbH (SWC), which provides thermosetting resins to the pharma industry, has developed two new product ...
ADCs need more efficient manufacturing processes
Welsh ADC Biotechnology, a company working to simplify and lower production costs for anti-cancer blockbuster drugs, ...
Global partnership to expand pharma biocatalysis uptake
Codexis, Inc. and Porton Pharma Solutions recently announced a strategic collaboration to deploy Codexis’ world-leading ...
Omyapharm for enhanced ODTs
Study findings underline the pleasant mouthfeel and excellent technical properties of the high purity mineral excipient
Zai Lab and Crescendo Biologics enter exclusive global license agreement
Agreement will develop, commercialise and manufacture a topical, innovative antibody VH domain therapeutic for ...
Performance validation: HPAPI containment testing in a risk-based era
Taking a more automated approach to validation testing paves the way to capturing more repeatable and reliable data, ...
New risk assessment on safe levels of opium alkaloids in poppy seeds
The European Food Safety Authority (EFSA) updated its risk assessment of opium alkaloids in poppy seeds, confirming ...
Ardena acquires Syntagon
Contract development and manufacturing organisation acquires a specialist contract manufacturer of novel active ...
Formulating for the modern consumer
Selecting the right excipient to make the perfect capsule
Highly potent APIs: hazards in classification and handling
This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk ...
CordenPharma expands oligonucleotide API manufacturing
The expansion, which was completed in Q1 2018, will make the Colorado, US site one of the largest oligonucleotide ...
Sterling invests £6m into pilot plant
The contract development and manufacturing organisation is investing £6m into its pilot plant facility in the UK, to ...
In Brief
Most Popular in Ingredients
Suppliers in ingredients
Reports
